Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder in which eosinophilic inflammation represents a treatable trait associated with increased exacerbation risk. Randomized trials (RCTs) of mepolizumab in eosinophilic COPD have shown variable results, and the magnitude of clinical benefit remains uncertain.MethodsWe performed a systematic review and meta-analysis of RCTs evaluating mepolizumab in eosinophilic COPD. Frequentist random-effects models were used to estimate pooled effects, and complementary Bayesian analyses were conducted to quantify the probability of treatment benefit.ResultsFour RCTs comprising 1,953 patients of whom 978 (50.1%) underwent mepolizumab were analyzed. Mepolizumab significantly reduced the annual rate of moderate or severe exacerbations (IRR 0.80; 95% CI: 0.75 to 0.86) and prolonged the time to first exacerbation (HR 0.78: 95% CI: 0.69 to 0.88). Bayesian analyses showed a posterior probability of high benefit for exacerbation-related outcomes. Similarly, a reduction in exacerbations requiring emergency care was observed (IRR 0.77; 95% CI: 0.60 to 1.00) with no increased risk for adverse events, treatment discontinuation, or mortality. Conclusion In eosinophilic COPD, mepolizumab reduces exacerbation frequency and delays time to first exacerbation without compromising safety. These findings support targeting IL-5-mediated eosinophilic inflammation in selected COPD populations.